First liver cancer patient dosed in the MIV-818 phase Ib study
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed in the phase Ib study of MIV-818. The MIV-818 phase I study (NCT03781934) consists of two parts: (i) the already completed phase Ia, which was a within-patient dose-escalation study, and (ii) the phase Ib between-patient dose-escalation study, a classic 3+3 dose-escalation multi-center study in patients with advanced liver cancer. The phase Ia study demonstrated a liver-cancer directed effect of MIV-818 and five out of nine patients were considered to